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Local cerebral blood ﬂowF) is a bioactive phospholipid that accumulates during ischemia-reperfusion and is
involved in the activation of platelets, neutrophils, and pro-inﬂammatory signaling. PAF has been suggested to
enhance brain ischemia-reperfusion damage. LAU-0901, a novel PAF receptor antagonist, was examined in
models of focal cerebral ischemia in rats and mice. Sprague–Dawley rats were anesthetized and received 2-
hour middle cerebral artery occlusion (MCAo) by intraluminal suture. LAU-0901 (30, 60, 90mg/kg; n=9–11) or
vehicle (n=11) was administered i.p. at 2 h after onset of MCAo. The neurological status was evaluated at
60 min, and on days 1, 2, 3 and 7 after MCAo. In the dose–response study in mice, C57BL/6 mice were
anesthetized and received 1 h MCAo by intraluminal suture. LAU-0901 (15, 30, 60 mg/kg; n=7–9) or vehicle
(n=8) was given i.p. at 1 h after onset ofMCAo. Local cerebral blood ﬂow (LCBF) wasmeasured at 1, 2, 4, and 6 h
afterMCAo inmice. LAU-0901 treated rats showed improved neurological score throughout the 7-day survival
period. LAU-0901 treatment (30, 60 and 90mg/kg) reduced total corrected infarct volume compared to vehicle
rats by 76, 88 and 90%, respectively. Mice treatedwith LAU-0901 (30 and 60mg/kg) reduced total infarction by
29% and 66%, respectively. LCBF was improved by treatment with LAU-0901 (30 mg/kg) by 77% of baseline at
6 h. In conclusion, we demonstrate for the ﬁrst time that LAU-0901 improves behavioral scores, LCBF and
reduces infarct volume after focal cerebral ischemia in rats andmice. Thus, this PAF receptor antagonist exhibits
potent and sustained neuroprotection that may be of value for the design of stroke therapies.
© 2008 Elsevier Inc. All rights reserved.IntroductionStroke is a major cause of death and disability. Only one drug is
approved for clinical use in stroke: a recombinant tissue plasminogen
activator, thrombolytic — which is effective in about 4% of patients
who suffer an acute ischemic stroke. The need to develop an effective
treatment for stroke, therefore, remains paramount.
Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phos-
phocholine) is a potent phospholipid mediator of leukocyte functions,
platelet aggregation and pro-inﬂammatory signaling. PAF accumulates in
response to cell injury, including cerebral ischemia-reperfusion. During
ischemia, PAF increases and then becomes a pro-inﬂammatorymessenger
as well as a mediator of neurotoxicity (Mukherjee et al., 1999; Chen and
Bazan, 2005). Excessive PAF promotes neuronal damage; inhibition of this
process plays a critical role in neuronal survival and prevention of ischemic
brain injury (Aspey et al., 1997; Tian and Bazan, 2005; Bozlu et al., 2007).
LAU-0901 (2,4,6-Trimethyl-1, 4-dihydro-pyridine-3, 5-dicarboxylic
acid) is a highly potent and selective PAF antagonist (Fig. 1) that inhibitsof Excellence 2020 Gravier Str,
: +1 504 599 0488.
l rights reserved.apoptosis, represses the chemotaxis of inﬂammatory cells, protects
photoreceptors from light-induced oxidative stress, and inhibits
inﬂammatory responses in retinal, corneal and neural cells (Bazan
et al., 2003; Cortina et al., 2005; He and Bazan, 2006; Boetkjaer et al.,
2007).However, LAU-0901has not been studied inexperimentalmodels
of focal cerebral ischemia. The doses of LAU-0901were chosen from our
previous studies. The dose–response study in vitro showed signiﬁcant
inhibition of amyloid- and cytokine-induced COX-2 RNA levels by LAU-
0901 at concentrations of 100 nM (Boetkjaer et al., 2007), and the in vivo
study of the light-induced retinal damage (Cortina et al., 2005) used a
dose of 30mg/kg of LAU-0901,whichwas highly neuroprotective in rats.
Thus, the present study was conducted to assess whether LAU-0901
would show neuroprotective efﬁcacy when administered in different
doses after middle cerebral artery occlusion (MCAo) in rats and mice.
Materials and methods
Animal preparation
Forty male Sprague–Dawley rats (Charles River Lab., Wilmington,
MA) weighing 280–360 g were fasted overnight but allowed free access
to water. All studies were approved by the Institutional Animal Care and
Fig. 2. Total neurological score (normal score=0; maximal score=12) in rats during
MCAo (1 h) and at various survival times after MCAo. LAU-0901 or vehicle treatments
were administered at 2 h after onset of ischemia. All doses of LAU-0901 signiﬁcantly
improved the neurological score at 24, 48, 72 h and 7 days compared to vehicle group.
Values shown are means±SEM. ⁎Signiﬁcantly different from corresponding vehicle
group (pb0.05).
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were anesthetized with isoﬂurane (3.5% for induction, 1% for main-
tenance), 70% nitrous oxide and a balance of oxygen, intubated (2.1 mm
O.D.×45 mm B&D Insyte catheter tubing, Becton Dickinson Infusion
Therapy Systems Inc., Sandy, UT) and mechanically ventilated with a
rodent respirator (Stoelting Co., Wood Dale, IL). Animals were immobi-
lized with pancuronium bromide (0.75 mg/kg i.v., and 0.35 mg/kg i.v.
every half-hour), and atropine (0.15 mg/kg i.p.) was administered to
diminish secretions. Rectal (CMA/150 Temperature Controller, CMA/
Microdialysis AB, Stockholm, Sweden) and cranial (left temporalis
muscle) (Omega Engineering, Stamford, CT) temperatures were mon-
itored and maintained at 36.0±0.5 °C during surgical procedure.
Middle cerebral artery occlusion in rats
The right middle cerebral artery (MCA) was occluded for 2 h by a
modiﬁcation (Belayev et al., 1996) of the intraluminal-suture occlusion
method (Zea Longa et al., 1989), in which a nylon ﬁlament is introduced
retrogradely into the MCA. In this method, the right common carotid
arterywasﬁrst exposed and theoccipital branches of theexternal carotid
artery (ECA)were coagulated.A3-0monoﬁlamentnylon suturewas then
passed via the proximal ECA into the internal carotid artery and, thence,
into the MCA, a distance of 20–22 mm from the carotid bifurcation
according to the animal's weight (Belayev et al., 1996). Prior to use, the
suture was coated with poly-L-lysine solution in order to enhance its
adhesion to the surrounding endothelium and increase the reproduci-
bility of the resulting infarct (Belayev et al., 1996). The neck incisionwas
then closed. Animals were allowed to awaken from anesthesia and, at
60min of MCAo, were tested on a standardized neurobehavioral battery
(Belayevet al.,1996) to conﬁrm thepresenceof ahigh-gradeneurological
deﬁcit. Rats that did not demonstrate an initial left upper extremity
paresis were excluded from further study. After 2 h of MCAo, rats were
re-anesthetized, temperature probes were reinserted, and the intralum-
inal suture was carefully removed. Incisions were closed and rats were
returned to their cages. After surgery rats were observed carefully for
signs of discomfort; no such signs were observed.
Middle cerebral artery occlusion in mice
Male C57BL/6 mice (Charles River Lab., Wilmington, MA) weighing
20–25 gwere anesthetizedwith 2% halothane, 70% nitrous oxide and a
balance of oxygen using a face mask. The body temperature (CMA/150
Temperature Controller, CMA/Microdialysis AB, Stockholm, Sweden)
was monitored and maintained at 37.0±0.5 °C during surgical
procedure. The right MCA was occluded for 1 h by the intraluminal-
ﬁlament method as previously described (Marcheselli et al., 2003). A
monoﬁlament suture was introduced retrogradely into the right
external carotid artery and advanced into the internal carotid artery
and MCA at a distance of 9–10 mm from the carotid bifurcation. After
1 h of MCAo, mice were re-anesthetized, the nylon suture was
removed, and animals were allowed to survive for 48 h.
Local cerebral blood ﬂow (LCBF) was monitored by laser Doppler
ﬂowmetry (Periﬂux System 5000; Perimed Inc, Sweden) throughout
the whole experiment. The laser Doppler probe was attached to theFig. 1. Chemical structure of LAU-0901.skull 2 mm posterior and 6 mm lateral to bregma for continuous
monitoring of LCBF in the MCA territory. Occlusion of the MCA was
conﬁrmed by documenting a N80% decline in relative cerebral blood
ﬂow. A return to 50% of baseline LCBF within 10 min of suture
withdrawal conﬁrmed a reperfusion of theMCA territory.Mice that did
not meet both ischemic and reperfusion ﬂow criteria were excluded
from the study. To examine the effect of LAU-0901 or vehicle treatment
on the LCBF, itwas continuouslymonitored and recorded beforeMCAo,
during 60 min of MCAo, and after reperfusion (at 1, 2, 4, and 6 h).
Treatment and experimental groups
The agents (LAU-504; 15, 30 60 or 90 mg/kg) or vehicle (45%
cyclodextran,1ml/kg)was administered i.p. at the time of reperfusion,
i.e., 2 h from onset of MCAo in rats and 1 h from onset of MCAo inmice.
Rats and mice were randomly assigned to the following groups
after MCAo:
Dose–response study in rats: (1) vehicle: 45% cyclodextran (n=11);
(2) LAU-0901, 30 mg/kg (n=9); (3) LAU-0901, 60 mg/kg (n=10) and
(4) LAU-0901, 90 mg/kg (n=10).
Dose–response study in mice: (1) vehicle: 45% cyclodextran (n=8);
(2) LAU-0901, 15 mg/kg (n=7); (3) LAU-0901, 30 mg/kg (n=9) and
(4) LAU-0901, 60 mg/kg (n=7).
LCBF study in mice: LAU-0901, 30 mg/kg (n=11), and vehicle (n=8).
Neurobehavioral evaluation in rats
A standardized battery of behavioral tests (Belayev et al., 1996) was
used to quantify sensorimotor neurological function in all 40 rats
beforeMCAo, at 60min after MCAo, and at 24, 48, 72 h and 7 days after
treatment. The battery consisted of 2 tests used to evaluate
neurological function: (1) a postural reﬂex test, to examine upper
body posture while the animal is suspended by the tail (Bederson
et al., 1986); and (2) a forelimb placing test, to examine sensorimotor
integration in forelimb placing responses to visual, tactile and
proprioceptive stimuli (De Ryck et al., 1989). Neurological function
was graded on a scale of 0–12 (normal score=0, maximal score=12) as
previously described (Belayev et al., 1996). Tests were conducted by an
observer blinded to the treatment groups.
Neurobehavioral evaluation in mice
Mice were examined for neurological deﬁcits on days 1 and 2 after
MCAo using a modiﬁed ﬁve-point Bederson scale (Bederson et al.,
255L. Belayev et al. / Experimental Neurology 214 (2008) 253–2581986). Normal motor function was scored as 0, failure to extend left
forepaw as 1, circling to the contralateral side as 2, lack of coordination
as 3, and no spontaneous motor activity as 4.
Histopathology in rats
Following a 7-day survival, animals were deeply anesthetized with
isoﬂurane and perfused transcardially with isotonic saline for 5 min
followed by ﬁxation with 4% paraformaldehyde for 20 min. Ten-
micron-thick sections were cut in the coronal plane and stained with
hematoxylin and eosin. To measure infarct size, histological sections
were digitized (MCID™ Core imaging software, InterFocus Imaging
Ltd, Linton, Cambridge, UK) at 7 standardized coronal levels (bregma
levels: +2.7, +1.2, −0.3, −1.3, −1.8, −3.8 and −5.0 mm) (Konig and
Klippel, 1963). An investigator blinded to the experimental groups
outlined cortical and subcortical (striatal) infarct areas (which were
clearly demarcated) as well as the left- and right-hemisphere contours
at each level. The corresponding tissue volumes were calculated by
numeric integration of the areas from all sections using Simpson's
method (Zhao et al.,1996). Infarct volumewas corrected for changes in
tissue water content (swelling) by applying the following formula:
Acorrected ¼ Ainfarct  1−
AI−AC
AC
 
where AI is the ipsilateral hemisphere area and AC is the contralateral
hemisphere area (Belayev et al., 2003).
Histopathology in mice
Micewere allowed to survive for 48 h after MCAo with free access to
food and water, then they were re-anesthetized with sodium pentobar-
bital. Brains were removed and placed in a freezer at −20 °C for up to
20 min to facilitate sectioning. Two-millimeter-thick coronal sections
were cut 2, 4, 6, 8 and 10 mm from the frontal pole using a brain matrix.Fig. 3. Time course of recovery of postural reﬂex, visual, tactile and proprioceptive contralat
rats. Bar graphs show improvement of placing reactions in LAU-0901-treated rats vs.
corresponding vehicle group (pb0.05).The sections were put in a glass Petri dish containing 2% TTC solution
(2,3,5-triphenyltetrazolium chloride). The dishes were covered with
aluminum foil to prevent exposure to light and incubated at 37 °C for
15 min. The TTC solution was then replaced with 10% buffered formalin.
The sections were photographed for quantitative histopathology. The
areas of right hemisphere, left hemisphere, and infarctionweremeasured
usingNIH imagepublic domain software (version 1.63) byan investigator
blinded to the study groups. The volumes of right and left hemispheres
and infarction were calculated according to the slice thickness of 2 mm
per slice, and infarct volume was corrected for swelling as described
(Doerﬂer et al., 2001). From these data, total infarction (expressed as a
percentage of the contralateral hemisphere) was computed.
Statistical analysis
Data are presented as mean values±SEM. Neurobehavioral scores
and infarct size data were analyzed by repeated-measures analysis of
variance (ANOVA) with post hoc Bonferroni tests. Physiological
variables were compared by Student t tests. Differences at pb0.05
were considered statistically signiﬁcant.
Results
Physiological variables
Therewereno signiﬁcant differenceswith respect to rectal and cranial
temperatures among the rat and mice experimental groups. Vehicle-
treated rats lost∼8–13% of bodyweight during the 7-day survival period.
On the other hand, animals treated with LAU-0901 (60 mg and 90 mg)
lost ∼2–7% of body weight and returned to baseline on day 7.
Neurological assessment
All rats had a total neurological score of 0 prior to ischemia; and all
animals developed a high-grade neurological deﬁcit (11; maximumeral forelimb placing reactions (normal score=0, maximal score=2) following MCAo in
vehicle-treated group. Values shown are means±SEM. ⁎Signiﬁcantly different from
Fig. 4. Cortical, subcortical and total infarct areas measured at 7 coronal levels and integrated infarct volumes in rats with 2-hour MCAo and on day 7 of survival. Rostrocaudal
distribution of cortical infarct area and cortical infarct volume (panels A and B), subcortical infarct area and subcortical infarct volume (panels C and D) and total infarct area and total
corrected infarct volume (panels E and F) in all groups. Data are presented as mean±SEM. ⁎Signiﬁcantly different from corresponding vehicle group (pb0.05).
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animals required exclusion on the basis of an inadequate degree of
cerebral ischemia during the neurological assessment. Vehicle-treated
animals continued to exhibit severe behavioral impairments through-
out the 7-day survival period. All doses of LAU-0901 signiﬁcantly
improved the neurological score compared with vehicle-treated rats
at 24, 48, 72 h and 7 days (Fig. 2). Fig. 3 depicts signiﬁcant
improvement of postural reﬂex, visual and tactile placing reactions
and proprioceptive placing at different times in LAU-0901 treated rats
compared to the vehicle group (Fig. 3). LAU-0901-treated mice
showed a signiﬁcant neurological improvement by 40% and 51% atFig. 5. Representative hematoxylin and eosin stained parafﬁn-embedded brain sections at tw
(30, 60 and 90 mg/kg) at 7 days after MCAo. A well-demarcated infarct involving cortical and
and subcortical infarction in rats treated with 30 mg/kg of LAU-0901. In contrast, two rats tr
(ZEISS microscope).48 h in the LAU-0901 30 and 60 mg/kg-treated groups, compared to
the vehicle group. Behavioral scores in LAU-0901-treated group with
15 mg/kg were not signiﬁcantly different from the vehicle group.
Histopathology
The dose–response study in rats revealed that neuroprotection was
extensive in neocortex (mean tissue salvage, 93% and 98%, respectively,
in the 60 and 90 mg/kg LAU-0901 groups) and spread across multiple
coronal levels (Figs. 4A and B). Fig. 4C demonstrates the rostrocaudal
distribution of subcortical infarct areas, which were smaller in all LAU-o coronal level (bregma +1.2 and −3.8 mm) from rats treated with vehicle and LAU-0901
subcortical regions is present in rats treated with vehicle. Note smaller area of cortical
eated with 60 and 90 mg/kg of LAU-0901 did not have infarction at these bregma levels
Fig. 7. Effect of LAU-0901 on local cerebral blood ﬂow (LCBF). Basal indicated no MCAo.
LAU-0901 (30 mg/kg; n=11) or vehicle (n=8) was administered IP at 1 h after onset of
reperfusion. LCBF was reduced to 15% during MCAo in all animals and increased to 41%
from baseline in vehicle-treated mice. In contrast, treatment with LAU-0901 increased
LCBF to 77% at 6 h compared to vehicle-treated mice. Values shown are means±SEM.
⁎Signiﬁcantly different from corresponding vehicle group (pb0.05).
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subcortical infarct volumewas also signiﬁcantly protected by treatment
with LAU-0901 (30, 60 and 90mg/kg) by 79%, 78% and 77%, respectively
(Fig. 4D). Treatment with LAU-0901 markedly reduced total (cortical
+subcortical) infarct areas compared to the vehicle group (Fig. 4E). Total
infarct volume corrected for brain swelling was reduced by a mean of
76%, 88% and 90%, respectively by treatmentwith LAU-0901 in the30, 60
and 90 mg/kg groups (Fig. 4F). The brains of vehicle-treated animals
with MCAo exhibited a consistent pannecrotic lesion involving both
cortical and subcortical (mainly striatal) regionsof the right hemisphere,
characterized microscopically by loss of neuronal, glial, and vascular
elements. By contrast, infarct sizewas dramatically reduced by all doses
of LAU-0901 therapy (Fig. 5).
In the dose–response study in mice, we measured the extent of
neuroprotection achieved with 30 and 60 mg/kg of LAU-0901, when
administered at 1 h after onset of MCAo (Fig. 6). Infarct volume,
expressed aspercentage of the corrected infarct volume in the ipsilateral
hemispheric volume, was signiﬁcantly reduced by 29% and 66% in the
LAU-0901 30 and 60 mg/kg-treated groups, compared to the vehicle
group. Infarct volumewas not signiﬁcantly different between LAU-0901
(15 mg/kg) and the vehicle-treated group.
LCBF decreased immediately after MCAo to 15% of basal and
remained decreased during 60 min of occlusion in two groups (Fig. 7).
Ten minutes after suture withdrawal, LCBF increased to 50% of basal,
remained at the same level during the next 2 h, and then gradually
decreased to 41% in the vehicle-treated group at 6 h. In contrast, LCBF
continually increased in mice treated with LAU-0901 (by 77%) of basal
at 6 h, compared to the vehicle-treated group (Fig. 7).
Eight animals died in our study: 3 rats in the vehicle group (died on
days 2, 3 and 4); 2 rats in the LAU-0901 30 mg/kg group (died on days
2 and 6) and 3 rats in the LAU-0901 60 mg/kg group (died on days 3, 5
and 6). No animal died in the LAU-0901 90 mg/kg group and in dose–
response and LCBF studies in mice.
Discussion
We have shown here for the ﬁrst time that the novel PAF receptor
antagonist, LAU-0901, confers robust neuroprotection in a widely
used, reproducible experimental model of focal cerebral ischemia. Our
results demonstrate that treatment with LAU-0901, when applied
immediately after reperfusion following a 2-hour focal ischemic insult
reduces the volume of cerebral infarction and improves the neurolo-
gical score compared to the vehicle group.
PAF is a membrane-derived bioactive phospholipid that has been
suggested to play an important role in brain ischemia and stroke (Bazan,Fig. 6. Dose–response study in mice. Infarct volume, expressed as percentage of the
corrected infarct volume in the ipsilateral hemispheric volume, was signiﬁcantly lower
in LAU-treated mice (30 and 60 mg/kg), as compared to the vehicle-treated group.
Values shown are means±SEM. ⁎Signiﬁcantly different from corresponding vehicle
group (pb0.05).2003). While basal levels of PAF are virtually undetectable in resting
tissues, PAF is rapidly synthesized in the brain during ischemia, mediates
the release of the neurotransmitter glutamate in the hippocampus, and
selectively activates a network of early response gene expression,
including the rapid induction of COX-2 and TNFα (Cui et al., 2007; He
and Bazan, 2006). During ischemia the rates of PAF synthesis and
degradation no longer maintain a modulated PAF pool size; PAF then
accumulates and becomes a pro-inﬂammatorymessenger and amediator
of neurotoxicity (Bazan, 2005). PAF levels are increased in gerbil brains in
response to 5 min of bilateral carotid occlusion at early stages of
reperfusion, and the naturally occurring PAF antagonist, BN 52021, has
been shown to be neuroprotective in this model (Panetta et al., 1989).
We have previously shown that PAF is involved in synaptic
plasticity and memory formation (Kato et al., 1994). Infusion of PAF
into speciﬁc brain regions promotes memory facilitation in rats. In
these experiments using the step-down inhibitory avoidance or
spatial-habitation task, when PAF was infused 10 min before or
immediately after training, animal retention scores were enhanced
(Izquierdo et al., 1995). However, when PAF infusion was delayed for
60 min after training, no effect on retention was observed. The role of
PAF in hippocampal synaptic plasticity and memory storage was
demonstrated using mice deﬁcient in PAF receptor, in which reduced
long-term potentiation (LTP) was detected (Chen et al., 2002).
PAF antagonists, after ischemia and reperfusion, has been shown to
be beneﬁcial in different animal models: myocardial reperfusion
injury in swine (Loucks et al., 2000), lung ischemia-reperfusion injury
in canine (Iwazaki et al., 2001), intestinal ischemia-reperfusion in
mouse (Souza et al., 2003), acute hepatic injury in rat (Grypioti et al.,
2008) and renal ischemia in rat (Lloberas et al., 2001).
Also, the neuroprotective effect of PAF inhibitors on neonatal rat
model has been demonstrated in hypoxic ischemic brain injury (Bozlu
et al., 2007), global cerebral ischemia in gerbils (Panetta et al., 1989)
and focal cerebral ischemia in rat (Aspey et al., 1997) and mouse
(Subbanna and Tyagi, 2006).
Unfortunately, a number of experimental stroke drugs have been
proved ineffective in human trials (for review, see O'Collins et al.,
2006). The possibility that species-related and even strain-related
differences may also play a role cannot be ruled out. It is well known
that the same surgical procedure for focal cerebral ischemia may
produce very different neuropathological outcomes in mice and rats.
For this reason, we established a dose–response relationship for
neuroprotection elicited by of LAU-0901 in both rat andmousemodels
of focal cerebral ischemia. The high degree of histological protection
was demonstrated with all doses of LAU-0901 in rats. Vehicle-treated
animals showed a large cortical and subcortical infarct at multiple
258 L. Belayev et al. / Experimental Neurology 214 (2008) 253–258coronal levels. By contrast, LAU-0901 treated rats signiﬁcantly reduced
cortical (by 93–98%), subcortical (77–79%) and total infarct volumes
(by 76–90%) compared to the vehicle group. The most remarkable
effect of LAU-0901 in rat study was found in the 60 and 90mg/kg LAU-
0901 treated groups. Mice treated with 30 and 60 mg/kg of LAU-0901
showed reduced total infarction, but not with 15 mg/kg.
The neuroprotective mechanism of LAU-0901 against focal cerebral
ischemia is not completely understood. We have previously shown that
PAF produces cerebral damage by stimulating leukocyte inﬁltration in
damagedneuronal tissue, increasing intracellular calciumconcentration,
disrupting the blood–brain barrier, and reducing cerebral blood ﬂow
(Bazan, 2005). The recovery of LCBF after 1 h ofMCAowas remarkable in
LAU-0901-treated mice. In contrast to the vehicle-treated group, LCBF
continually increased inmice treatedwith LAU-0901 (by 77%) of baseline
at 6 h. Cerebral blood ﬂow improvement is therefore a likely explanation
for the smaller infarction in the cortical and, especially, in subcortical
area, which is usually very resistant to therapeutic interventions. Further
studies are needed to investigate the exact mechanism by which LAU-
0901 protects the brain after focal cerebral ischemia.
Functional deﬁcits in rodents due to MCAo represent approxi-
mately the outcome in patients. Stroke produced by focal cerebral
ischemia is commonly associated with impaired sensorimotor and
cognitive function. Approximately 70% to80%of all patients experience
hemiparesis immediately after stroke. AfterMCAo, rodents also exhibit
a behavioral deﬁcit characterized by sensorimotor dysfunction. We
have shown here that administration of all three doses of LAU-0901
signiﬁcantly improved the neurological score compared with vehicle
through the 7-day survival period. There were no adverse behavioral
side effects observed with LAU-0901 administration.
The beneﬁcial effect of LAU-0901has been shown in awell-controlled
animal model of MCAo in rats (Belayev et al., 1996). Intraluminal-suture
occlusion of theMCAhas become increasingly popular as a focal ischemia
model because of its relative simplicity andminimally invasive nature. In
the present study and in recently published observations, we have used a
poly-L-Lysine-coated suture and have found that this technique leads to
reliable and highly consistent results (coefﬁcient of variation of infarct
volume, 9%) (Belayev et al., 1996). It produces consistent cortical plus
subcortical infarct that closely mimics in extent and severity the large
hemispheric infarcts resulting from proximal MCA and internal carotid
artery occlusions in humans. Essential to the consistency of the model is
the closemonitoring bodyand cranial temperatures. Cranial temperature
control is extremely important, as it is an essential determinant of the
extent of brain injury (Ginsberg and Busto, 1998).
In summary, our results have shown for the ﬁrst time that the
novel the PAF inhibitor, LAU-0901 (systemically administered), is
markedly neuroprotective in acute focal cerebral ischemia in rat and
mice, both improving behavioral function and reducing the extent of
histological damage with a therapeutic window of at least 2 h.
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